Cognos Recognizes Phase Forward for Excellence in Life Sciences Innovation.Phase Forward Named Best Life Sciences Partner; Electronic Data Capture (EDC EDC See: Export Development Corp. ) Product InForm[TM] Best Software-as-a-Service WALTHAM, Mass. -- Phase Forward (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that it has received two Global Partner Awards from Cognos: "Best Life Sciences Partner" and "Best Software-as-a-Service (SaaS)." The awards recognize partners excelling at innovation, influence and thought leadership. In addition, Phase Forward's InForm[TM] Integrated Trial Management (ITM ITM See: In-the-money ) system (version 4.5) has achieved "Powered by Cognos" status. Phase Forward leverages Cognos technology to provide a robust solution for generating clinical trial data reports and analyzing data. With timely and insightful views into trial data, sponsors have the ability to mitigate risks and improve overall trial conduct. "Life sciences companies are under intense pressure to deliver new drugs in record time and Phase Forward's flexible set of out-of-the-box reporting and analysis tools help streamline a previously time-intensive reporting process," said Bill Stevens William Henry Stevens (born October 15, 1969) is an American journalist. As of this fall, he will serve as the noon and 6 p.m. anchor at WPVI-TV in Philadelphia, Pennsylvania, demoted from 11 PM. He works alongside Liz Yang. , senior director, Life Sciences Solutions, Cognos. "The combination of our technologies helps facilitate better clinical trial information access and lets study teams focus on clinical data analysis and action - not report creation and maintenance." "Our longstanding strategic alliance with Cognos has proven to be a powerful competitive advantage, and this latest acknowledgement speaks to the stability and scalability of our products," said Steve Rosenberg, Senior Vice President, Phase Forward. "Cognos' breadth of business intelligence experience and depth of expertise help us to deliver the solutions that turn clinical trial data into actionable information - and help users make better informed decisions as a result." Award winners were announced at the Partner Summit Awards ceremony held at the recent Global Partner Summit as part of Cognos Forum 2007. About Phase Forward Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm[TM]), clinical data management (Clintrial[TM]), clinical trials signal detection (CTSD CTSD Crew and Thermal Systems Division CTSD Certified Trading System Developer CTSD Computer Test Sequences Document (NASA) CTSD Coordinate Transformation System (NASA) CTSD Combat Training Support Directorate [TM]), strategic pharmacovigilance (WebVDME[TM] and Signal Management), adverse event reporting (Clintrace[TM]) and applied data standards (WebSDM[TM]). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization Process optimization is the practice of making changes or adjustments to a process, to get results. Optimization is the use of specific techniques to determine the most cost effective and efficient solution to a problem or design for a process. , safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 250 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, , Dana-Farber Cancer Institute, Eli Lilly Eli Lilly can refer to:
abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , GlaxoSmithKline, Harvard Clinical Research Institute, Merck & Co., Merck Serono In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family. The Merck-Serono merger was announced on September 21, 2006. Merck KGaA and Serono operated as distinct entities until at least January 2007. , Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles Quintiles Transnational Corp. is a contract research organization which serves the pharmaceutical, biotechnology and healthcare industries. History Quintiles was founded in 1982 by Dennis Gillings and as of 2007 it has 18,000 employees. , sanofi-aventis, Schering-Plough Research Institute, Tibotec, the U.K. Medicines and Healthcare Products Regulatory Agency The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK government agency which is responsible for ensuring that medicines and medical devices work and are acceptably safe. and Servier. Additional information about Phase Forward is available at www.phaseforward.com. About Cognos Cognos, the world leader in business intelligence and performance management solutions, provides world-class enterprise planning and BI software and services to help companies plan, understand and manage financial and operational performance. Cognos brings together technology, analytical applications, best practices, and a broad network of partners to give customers a complete performance system. The Cognos performance system is an open and adaptive solution that leverages an organization's ERP (Enterprise Resource Planning) An integrated information system that serves all departments within an enterprise. Evolving out of the manufacturing industry, ERP implies the use of packaged software rather than proprietary software written by or for one customer. , packaged applications, and database investments. It gives customers the ability to answer the questions - How are we doing? Why are we on or off track? What should we do about it? - and enables them to understand and monitor current performance while planning future business strategies. Cognos serves more than 23,000 customers in more than 135 countries, and its top 100 enterprise customers consistently outperform market indexes. Cognos performance management solutions and services are also available from more than 3,000 worldwide partners and resellers. For more information, visit the Cognos Web site at http://www.cognos.com. Cautionary Statement Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services and the ability of Phase Forward's customers to realize benefits from the use of Phase Forward's products and services. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers to realize benefits from the use of its products and services, changes in regulatory requirements applicable to Phase Forward's customers, the manner in which Phase Forward's customer and partner and its partner's customers conduct business and the possibility that their needs or plans may change over time, and competition. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Quarterly Report on Form 10-Q Form 10-Q See 10-Q. . |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion